How quickly a programme reaches IND depends less on the length of individual studies than on how well scientific, operational and regulatory decisions connect along the way. In this on-demand webinar hosted by Fierce Biotech, Evotec development leaders take apart a real case: a Dewpoint Therapeutics programme that moved from candidate selection to IND filing in 16 months through integrated drug development.
Watch to learn:
- How early scientific strategy and development planning shape the timeline to IND
- Where IND-enabling studies typically lose time, and how integrating toxicology, API development and regulatory strategy reduces that risk
- What leadership and partnership between sponsor and development team look like when a novel therapy is on the clock
Thank you! Your details have been received. Enjoy the webinar.
If the webinar has not loaded above, please click the link here.
